Detection of all isoforms of human leukocyte antigen G in maternal serum could be clinically applied for prediction of preeclampsa.

OBJECTIVE: Previously, a number of previous studies on human leukocyte antigen G (HLA-G) and preeclampsia (PE) have demonstrated that expression of HLA-G is significantly reduced in women with PE. However, no study has confirmed whether maternal serum HLA-G could be used as a clinical test when HLA-G1/-G5 isoforms were measured. Therefore, the present study is to develop a novel HLA-G ELISA which is able to detect all isoforms of HLA-G and then to perform a retrospective case-control study to investigate clinical significance of maternal serum HLA-G for predicting PE. METHODS: A recombinant HLA-G fragment which containing partial sequences of HLA-G α1 and α2 domains was constructed to develop two novel monoclonal antibodies against HLA-G. A novel HLA-G sandwich ELISA which could detect all isoforms of HLA-G was developed. By using the ELISA, predictive effectiveness of maternal serum HLA-G in a retrospective case control study was evaluated. RESULTS: At the first trimester and early second trimester, detection of maternal serum HLA-G had the sensitivity of 54.3% and 48.5% and the specificity of 97.8% and 96.3% in the prediction of PE. These were significantly higher than those at the third trimester (P < 0.05). CONCLUSION: HLA-G isoforms other than HLA-G1/-G5 are expressed in some pregnant women who have low level or lack HLA-G1/-G5. Measurement of all HLA-G isoforms in maternal serum could be used as a clinical test for early prediction of PE.

An autoantibody against a 48-Kd fragment of human DNA-topoiomerase I in breast cancer: Implication for diagnosis and prognosis, and antibody-dependent cellular cytotoxicity in vitro.

Previously, we reported a novel tumor-associated antigen (TAA) derived from human DNA-topoiomerase I (TOP 1). In the present study, we demonstrated that the autoantibody against the TAA could be a potential biomarker in the early diagnosis and favorable prognosis of patients with breast cancer (BC). To understand the survival benefits in BC patients, we investigated whether the autoantibody could induce antibody-dependent cellular cytotoxicity activities (ADCC) against breast cancer cells in vitro. We found that the autoantibody exhibited significant ADCC activities that destroyed breast cancer MCF-7 and MDA-MB-231cells with peripheral blood mononuclear cells (PBMCs). The ADCC activities of the autoantibody were significantly correlated with the number of natural killer (NK) cells, NKT cells, and CD4+/CD8+ T cells. Accordingly, our findings showed that the autoantibody not only represented an early index of immune response to the TAA, but also was involved in host immune defense mechanisms that initiated the destruction of cancer cells.